[go: up one dir, main page]

NO20023879L - Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt - Google Patents

Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Info

Publication number
NO20023879L
NO20023879L NO20023879A NO20023879A NO20023879L NO 20023879 L NO20023879 L NO 20023879L NO 20023879 A NO20023879 A NO 20023879A NO 20023879 A NO20023879 A NO 20023879A NO 20023879 L NO20023879 L NO 20023879L
Authority
NO
Norway
Prior art keywords
treatment
fatty acid
heart failure
congestive heart
acid oxidation
Prior art date
Application number
NO20023879A
Other languages
English (en)
Other versions
NO20023879D0 (no
Inventor
Andrew A Wolff
Brent K Blackburn
Hani Naief Sabbah
William Clark Stanley
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20023879D0 publication Critical patent/NO20023879D0/no
Publication of NO20023879L publication Critical patent/NO20023879L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20023879A 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt NO20023879L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356000P 2000-02-18 2000-02-18
US21990800P 2000-07-21 2000-07-21
PCT/US2001/004887 WO2001060348A2 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
NO20023879D0 NO20023879D0 (no) 2002-08-15
NO20023879L true NO20023879L (no) 2002-08-15

Family

ID=26879274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023879A NO20023879L (no) 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Country Status (17)

Country Link
US (2) US6528511B2 (no)
EP (2) EP2033633A3 (no)
JP (1) JP2004505886A (no)
KR (1) KR20020075801A (no)
CN (1) CN1227004C (no)
AR (1) AR033510A1 (no)
AU (1) AU778203B2 (no)
BR (1) BR0108452A (no)
CA (1) CA2398691A1 (no)
HK (1) HK1048250A1 (no)
IL (1) IL151014A0 (no)
MX (1) MXPA02007639A (no)
NO (1) NO20023879L (no)
NZ (1) NZ520780A (no)
TW (1) TWI235655B (no)
WO (1) WO2001060348A2 (no)
ZA (1) ZA200206451B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505886A (ja) * 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
JP2005507754A (ja) * 2001-11-08 2005-03-24 アトリウム メディカル コーポレイション 治療薬を含有するコーティングを有する管腔内装置
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7125876B2 (en) * 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
JP2007514769A (ja) * 2003-12-18 2007-06-07 シーブイ・セラピューティクス・インコーポレイテッド １−アルカン−２−オール置換ピペラジンおよびピペリジン化合物
EP2298862B1 (en) † 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
EP1812022B1 (en) 2004-09-28 2014-01-15 Atrium Medical Corporation Stand-alone film and methods for making the same
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) * 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US20060088596A1 (en) 2004-09-28 2006-04-27 Atrium Medical Corporation Solubilizing a drug for use in a coating
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20060111361A1 (en) * 2004-11-09 2006-05-25 Brent Blackburn Method of reversing left ventricle remodeling
JP2008533044A (ja) * 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド 内皮機能不全、アンギナおよび糖尿病のための組合せ治療
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) * 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
EP2051748A2 (en) * 2006-09-08 2009-04-29 Symphony Medical, INC. Intramyocardial patterning for global cardiac resizing and reshaping
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057344A2 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Coated surgical mesh
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
WO2008101002A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EP2146667A2 (en) * 2007-04-11 2010-01-27 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
KR20110013348A (ko) * 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 통증 치료를 위한 라놀라진의 용도
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
MX2012003362A (es) * 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
ES2414384T3 (es) * 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5001193A (en) 1988-12-22 1991-03-19 American Cyanamid Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base
DE69033967T2 (de) * 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505886A (ja) * 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
EP1259493A2 (en) * 2000-02-22 2002-11-27 Cv Therapeutics, Inc. Substituted piperazine compounds

Also Published As

Publication number Publication date
ZA200206451B (en) 2003-12-31
EP1259230A2 (en) 2002-11-27
AU778203B2 (en) 2004-11-25
WO2001060348A3 (en) 2002-01-31
NO20023879D0 (no) 2002-08-15
EP2033633A3 (en) 2009-07-08
HK1048250A1 (zh) 2003-03-28
WO2001060348A2 (en) 2001-08-23
US6677342B2 (en) 2004-01-13
EP2033633A2 (en) 2009-03-11
AU4150501A (en) 2001-08-27
IL151014A0 (en) 2003-02-12
TWI235655B (en) 2005-07-11
BR0108452A (pt) 2003-04-01
CA2398691A1 (en) 2001-08-23
US20030119718A1 (en) 2003-06-26
KR20020075801A (ko) 2002-10-05
CN1227004C (zh) 2005-11-16
MXPA02007639A (es) 2004-08-23
US6528511B2 (en) 2003-03-04
CN1420766A (zh) 2003-05-28
JP2004505886A (ja) 2004-02-26
US20010047000A1 (en) 2001-11-29
NZ520780A (en) 2006-04-28
AR033510A1 (es) 2003-12-26

Similar Documents

Publication Publication Date Title
NO20023879D0 (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
NO20030249D0 (no) Oksygenerte estere av 4-jod-fenylamino-benzohydroksamsyrer
NO20033304D0 (no) Essensielle N-3 fettsyrer i kardialinsuffisiens- og hjertesviktterapi
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20000877D0 (no) Forbedret syrekorrosjonsinhibitor
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE546425T1 (de) Herstellung von (r)-2-alkyl-3-phenylpropionsäuren
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
NO20030295D0 (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE602004022034D1 (de) Herstellung von konjugierten linolsäuren und linolsäuresalzen
NO20024488L (no) Anvendelse av melkesyrebakterier for behandling av bukhinnebetennelse
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60119076D1 (de) Gebrauch von Pyrometerdaten um Oxydation festzustellen
DE60143052D1 (de) Lipid vom carbonsäuretyp
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60042161D1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
DE60010725D1 (de) Herstellung von arylcarbonsäureestern
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
EE200300013A (et) Bispidiini uued ühendid ning nende kasutamine südame arütmia ravis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application